Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator

Compounds of Formula (I) pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the s...

Full description

Saved in:
Bibliographic Details
Main Authors Hsia, Clara, Mccartney, Jason, Ferris, Lori, Cleveland, Thomas, Young, Timothy, Uy, Johnny, Gulevich, Anton, Termin, Andreas P, Abela, Alexander Russell, Krenitsky, Paul John, Alcacio, Timothy, Pierre, Fabrice Jean Denis, Stavropoulos, Kathy, Grootenhuis, Peter Diederik, Shi, Yi, Khatuya, Haripada, Hughes, Robert M, Gross, Raymond, Hadida Ruah, Sara Sabina, Angell, Paul, Clemens, Jeremy, Kang, Ping, Siesel, David Andrew, Baek, Minson, Joshi, Pramod Virupax, Paraselli, Prasuna, Zhou, Jinglan, Van Goor, Fredrick, Miller, Mark Thomas, Shrestha, Muna, Anderson, Corey, Keshavarz-Shokri, Ali
Format Patent
LanguageEnglish
Published 24.11.2023
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:Compounds of Formula (I) pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed. Also disclosed are solid state forms of Compound 1 and salts and solvates thereof.
Bibliography:Application Number: NZ20170754805